Vasodilatory Shock
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 programAngiotensin II InjectionPHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
2030
Innoviva Specialty TherapeuticsAngiotensin-II
Chia Tai TianQing Pharmaceutical GroupAngiotensin II Injection
Clinical Trials (2)
Total enrollment: 244 patients across 2 trials
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Start: Sep 2025Est. completion: Jun 203030 patients
Phase 4Enrolling By Invitation
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
Start: Jul 2024Est. completion: Dec 2027214 patients
Phase 3Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 244 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.